Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 2/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111170 | 0.92 | MAPK14 (0.31) | MAPK14 | |
| SCHEMBL3119013 | 0.84 | TYK2 (0.36) | CDK5CDK5R1JAK2KCNH2 | |
| SCHEMBL3113114 | 0.83 | MAPK14 (0.33) | MAPK14 | |
| SCHEMBL3113159 | 0.83 | MAPK14 (0.33) | MAPK14 | |
| SCHEMBL3113599 | 0.83 | MAPK14 (0.33) | MAPK14 | |
| SCHEMBL1267319 | 0.78 | MAPK14 (0.32) | MAPK14KCNH2 | |
| SCHEMBL1266485 | 0.78 | MAPK14 (0.32) | MAPK14KCNH2 | |
| SCHEMBL3124399 | 0.77 | RAB9A (0.32) | — | |
| SCHEMBL3835719 | 0.76 | MAPT (0.32) | — | |
| SCHEMBL3835724 | 0.76 | MAPT (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179185-A1 | Novel Aminothienopyridinone Derivatives Processes for Preparing Them and Pharmaceutical Compositions Thereof | UCB PHARMA, S.A. (BE) | 2010-07-15 | — | — | US | claimed |
| US-20100179185-A1 | Novel Aminothienopyridinone Derivatives Processes for Preparing Them and Pharmaceutical Compositions Thereof | UCB PHARMA, S.A. (BE) | 2010-07-15 | — | — | US | disclosed |
| EP-2099805-A2 | NOVEL AMINOTHIENOPYRIDINONE DERIVATIVES PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS THEREOF | UCB Pharma S.A. (BE) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008064829-A2 | NOVEL AMINOTHIENOPYRIDINONE DERIVATIVES PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS THEREOF | UCB PHARMA, S.A. (BE) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179185-A1 | Novel Aminothienopyridinone Derivatives Processes for Preparing Them and Pharmaceutical Compositions Thereof | AASDHPPT, PTMS, TPMT | CDK5 1146/4885CDK5R1 1064/4885MAPK14 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.